Caris Life Sciences, Inc. research snapshot
CAI AI stock analysis as of the August 3, 2026 data cutoff reads Caris Life Sciences as a high-growth precision medicine business whose financials are improving faster than its stock price. The analysis is not a certain price prediction. At the July 31, 2026 close the stock was $15.67, market capitalization was about $4.43 billion, and the refresh re-verified FY2025 revenue of $812.03 million up 97%, FY2025 gross margin of 66.4%, first positive operating income of $45.11 million, a narrowed GAAP net loss of $68.09 million, positive operating cash flow of $83.16 million, and free cash flow of $66.9 million. Q1 2026 revenue of $216.2 million grew 79% year over year, EPS was breakeven at $0.00 against a $0.02 consensus loss, and management reaffirmed 2026 revenue guidance of $1.0 billion to $1.02 billion. The main question is whether the improving fundamentals can overcome a stock that closed 63% below its $42.50 all-time high, sits below its 50-day and 200-day moving averages, carries a Barchart 100% sell technical opinion, and faced a broad round of analyst price target cuts in July 2026. This is informational research and not investment advice.
Current price
$15.67
Market cap
$4.43 billion
AI score
60 / 100
Rating
Improving fundamentals with a broken price trend
Trend status
Below the 50-day and 200-day moving averages, Barchart technical opinion at 100% sell, near the 52-week low
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Caris Life Sciences sells tissue-based and blood-based comprehensive genomic profiling (MI Profile and Caris Assure) plus AI-powered products (GPSai) to oncologists, hospitals, and biopharma partners. FY2025 revenue reached $812.03 million up 97%, with molecular profiling services contributing $766.72 million and pharma R&D services $45.31 million. The model gains from recurring test volumes, drug development collaborations, and an expanding product menu including the Caris Detect early cancer detection blood test. | Medium-high |
| Moat | The moat comes from a large proprietary clinico-genomic database built over 15 years, AI analysis platforms (GPSai, MI Profile), CLIA-certified labs, and established biopharma relationships. Competition is real: Foundation Medicine (Roche), Guardant Health, and Tempus hold similar data assets, and Tempus trades on the same AI-driven precision medicine narrative. | Medium |
| Management | Founder and CEO David D. Halbert has led the company since 2008 from a pathology lab to a NASDAQ-listed AI TechBio company. Management delivered FY2025 operating profitability, positive free cash flow, Q1 2026 revenue growth of 79%, and a $100 million share repurchase authorization announced June 8, 2026. A NYSE Texas dual listing followed on June 17, 2026. Key-person risk remains in the founder-led structure, and the public market track record is only about one year. | Medium |
| Financial trend | Revenue grew from $306.13 million (FY2023) to $812.03 million (FY2025), a 2.7x increase in two years. Gross margin expanded from 29.17% to 66.40% over the same period. Operating income turned positive at $45.11 million in FY2025, net loss narrowed from $462.53 million (FY2023) and $378.26 million (FY2024) to $68.09 million, and operating cash flow and free cash flow both turned positive at $83.16 million and $66.9 million. Q1 2026 revenue of $216.2 million grew 79% with a 65% gross margin and breakeven EPS. | Medium-high |
| Valuation | At $15.67, CAI trades at 4.88x TTM revenue (P/S), 7.46x book value, and about 35.9x free cash flow with no meaningful P/E because GAAP profitability is not sustained. Enterprise value near $4.04 billion equals about 4.45x TTM revenue. The multiples are moderate for a company growing near 100%, but they still embed high expectations for continued growth and eventual profitability. | Medium |
| Technical trend | CAI closed at $15.67 on July 31, 2026, well below its 50-day moving average near $16.88 and 200-day moving average near $21.65, and only about 10% above the 52-week low of $14.19. The all-time high from August 2025 was $42.50, leaving the stock 63% below it. Barchart rates the technical opinion at 100% sell, and the 14-day RSI near 41.43 shows weak momentum, not oversold extremes. | Medium |
| Risk level | Elevated. Risks include competition in precision oncology, reimbursement uncertainty, reliance on biopharma partner revenue, a short public history (IPO June 2025), high implied volatility near 92%, the July 2026 wave of analyst target cuts, and the risk that revenue growth decelerates as the base expands. The 52-week decline of 46.88% shows the market has already re-priced the stock sharply. | High |
| AI confidence | Medium confidence for the business model, filed financials, revenue growth, margin path, cash position, and valuation math, all re-verified on August 3, 2026. Lower confidence for future growth rates, GAAP profitability timing, competitive evolution, and price scenarios because the public track record is short and analyst targets moved down materially in July 2026. | Medium data confidence |
| Investment certainty | Low. The fundamental trend is improving and analyst consensus is Buy with a $27.00 target, but the price trend is broken, technicals are weak, and targets have been cut across the sell side. The stock outcome depends on sustained high growth, a credible path to GAAP profitability, and whether sentiment turns after the August 5, 2026 Q2 report. | Low |
CAI AI stock forecast
The CAI AI stock forecast uses scenario ranges around the $15.67 July 31, 2026 close. It does not claim that AI can predict a specific future price. The bullish case requires sustained 40% plus revenue growth, continued margin expansion toward sustained GAAP profitability, and a market re-rating closer to analyst targets. The base case assumes growth decelerates toward 25 to 40% with steady margin improvement and a stock that builds a base before recovering. The bearish case assumes growth slows sharply, competition intensifies, or profitability slips further out.
$26 to $34
More likely if Caris maintains 40% plus revenue growth, gross margins hold above 65%, GAAP profitability is reached within the next few quarters, Q2 2026 results on August 5 beat expectations, and the market re-rates the stock toward the upper range of analyst targets (BTIG at $32, TD Cowen at $30, JPMorgan at $30).
$15 to $24
More likely if revenue growth decelerates to 25 to 40%, operating margins keep improving but GAAP profitability remains several quarters away, competitive pressure from Foundation Medicine and Tempus continues, and the stock trades between current levels and the consensus target of $27.00 while it digests the July price target cuts.
$8 to $13
More likely if revenue growth drops below 25%, gross margin gains stall, reimbursement changes cut testing volumes, competitive pricing pressure builds, or the company needs to raise capital despite its cash position. A break below the $14.19 52-week low would make this scenario more probable.
CAI AI technical analysis
CAI AI technical analysis starts from the July 31, 2026 close of $15.67 used for this August 3 static page. Barchart and StockAnalysis.com technical data show the stock below its 50-day moving average near $16.88 and 200-day moving average near $21.65, roughly 10% above the 52-week low of $14.19, with a Barchart technical opinion of 100% sell. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $15.67 | July 31, 2026 close, the latest verified print used for this August 3, 2026 data cutoff. |
| Near support | $15.22 | Barchart first support level near the July 31 close. A hold here keeps the recent $14.19 to $16 range intact. |
| Secondary support | $14.31 to $14.77 | Barchart second and third support levels. A close through this zone would test the 52-week low at $14.19. |
| 52-week low | $14.19 | Set May 13, 2026. A decisive break below this level would signal a new leg down and weaken the fundamental recovery thesis. |
| Near resistance | $16.13 | Barchart first resistance point just above the current price, near the 50-day moving average around $16.88. |
| Key resistance | $16.59 to $17.04 | Barchart second and third resistance points. A close above $17 with volume would improve momentum and target the July 2 high near $19.67. |
| 50-day moving average | Approximately $16.88 | StockAnalysis.com 50-day moving average. The stock has traded below this level recently, confirming weak near-term momentum. |
| 200-day moving average | Approximately $21.65 | StockAnalysis.com 200-day moving average. CAI is well below this level, keeping the long-term downtrend in effect. |
| Momentum | RSI near 41.43, Barchart 100% sell | The 14-day RSI sits near 41.43, below neutral, and the Barchart technical opinion is a 100% sell with an average short-term outlook. |
| Volume | 20-day average about 3.56 million shares | Trading was about 3.51 million shares on July 31. Volume expansion on up days would be a more constructive signal for a reversal attempt. |
| Volatility | Implied volatility near 92%, historical volatility near 47% | Option implied volatility sits near 92% with historical volatility near 47%, a wide gap that reflects uncertainty around the August 5 earnings report and the stock being a recent IPO. Position sizing must account for this. |
| Invalidation | Close below $14.19, then $13.00 | A daily close below the $14.19 52-week low would suggest a new leg down. A break below $13.00 would challenge the entire growth thesis and the analyst Buy consensus. |
CAI AI trading strategy
The CAI AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed fundamentals, technical confirmation, position sizing, and clear invalidation levels. Because CAI is a high-growth stock with a broken price trend, high implied volatility near 92%, and a binary event in the August 5, 2026 Q2 report, position size should be small and the invalidation levels must be respected.
Do not chase the stock while it sits below the 50-day and 200-day moving averages with a 100% sell technical opinion. A trend-following entry becomes valid only after CAI reclaims the 50-day moving average near $16.88, breaks above the $16.59 to $17.04 resistance zone on expanding volume, and ideally follows a Q2 report that confirms the growth and margin story.
A failed breakout, a close back below $16, or a reversal below the July 31 close would reduce confidence. The downtrend from $42.50 is intact until the stock reclaims the 200-day moving average near $21.65.
If CAI pulls back toward the $14.19 to $15.22 support zone without a break of the growth thesis, a cautious mean-reversion approach could be considered with price stabilization and declining downside volume. This is a high-risk approach in a stock already down 63% from its high, and the August 5 earnings report makes it especially dangerous to trade before results.
Do not average down solely because the stock is cheap. Define a maximum position loss and a hard stop below $14.19. Mean-reversion in a downtrend against an earnings catalyst is inherently risky.
Track quarterly revenue growth, molecular profiling test volumes, gross margin, operating income, cash burn, free cash flow, and management guidance. The next catalyst is the Q2 2026 report on August 5, 2026, against 2026 guidance of $1.0 billion to $1.02 billion. Watch whether analysts stabilize their targets after the July cuts and whether the $100 million buyback proceeds.
Lower conviction if revenue growth decelerates below 25%, gross margin compresses, operating losses re-appear, or management signals a need for capital. Track analyst target revisions and insider behavior given the founder-led structure.
Investment research summary
Caris Life Sciences sells comprehensive genomic profiling tests (tissue-based MI Profile and blood-based Caris Assure) plus AI-powered analysis (GPSai) that guide cancer treatment and drug development. Revenue comes from molecular profiling services (FY2025: $766.72 million) and pharma R&D partnerships ($45.31 million), with an expanding product pipeline including the Caris Detect early cancer detection blood test.
Caris' moat comes from a proprietary clinico-genomic database accumulated over 15 years, AI-powered analysis platforms, CLIA-certified lab infrastructure, and biopharma trial-matching relationships. The moat is real but not unique: Foundation Medicine (Roche), Guardant Health, and Tempus have comparable data and resources, so differentiation depends on data scale, product breadth, and execution rather than exclusive assets.
The thesis can fail if: (1) revenue growth decelerates sharply as the base expands; (2) gross margins stall under payer or competitive pricing pressure; (3) GAAP profitability stays out of reach and the company needs dilutive capital; (4) a competitor builds a better AI diagnostic platform; or (5) Medicare or private payer reimbursement changes reduce test volumes. The 63% drawdown from the all-time high shows the market already prices in meaningful downside risk.
Founder and CEO David D. Halbert has led Caris since 2008 and executed the transition from pathology lab to NASDAQ-listed AI TechBio company with $812.03 million in FY2025 revenue, first positive operating income, positive free cash flow, and a $100 million share repurchase authorization in June 2026. The founder-led structure creates key-person risk, and management has only about one year of operating under public market scrutiny.
Precision oncology is a secular growth market driven by biomarker research, FDA approvals for targeted therapies, wider adoption of comprehensive genomic profiling, and AI integration in diagnostics. The global precision medicine market is estimated above $100 billion and growing. Caris sits in the high-growth molecular diagnostics segment, competing with Tempus, Foundation Medicine, and Guardant Health for share of a market still in early adoption.
At $15.67, CAI trades at 4.88x TTM revenue, 7.46x book value, and about 35.9x free cash flow with no sustained GAAP earnings. Enterprise value near $4.04 billion equals about 4.45x TTM revenue. The margin of safety is limited because the valuation already assumes continued high growth and eventual profitability. If growth falls below 25% or profitability slips, the current multiple offers little downside protection.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CAI price | $15.67 at the July 31, 2026 close | Barchart and StockAnalysis.com quote pages | August 3, 2026 |
| Market capitalization | $4.43 billion, re-verified as $15.67 x 282.68 million shares | financial_rigor.py market cap verification and Barchart shares outstanding | August 3, 2026 |
| FY2025 revenue | $812.03 million, up 96.97% from $412.26 million in FY2024 | StockAnalysis.com financials and Barchart annual income statement | August 3, 2026 |
| FY2025 gross margin | 66.40%, up from 43.37% in FY2024 and 29.17% in FY2023 | StockAnalysis.com financials (gross profit $539.17 million / revenue $812.03 million) | August 3, 2026 |
| FY2025 operating income | +$45.11 million, first positive year | StockAnalysis.com financials operating income line | August 3, 2026 |
| FY2025 net income | -$68.09 million GAAP net loss, narrowed from -$378.26 million in FY2024 | StockAnalysis.com financials and Barchart annual income statement | August 3, 2026 |
| FY2025 operating cash flow | +$83.16 million, first positive year | StockAnalysis.com cash flow statement | August 3, 2026 |
| FY2025 free cash flow | +$66.9 million, first positive year | StockAnalysis.com cash flow statement | August 3, 2026 |
| Q1 2026 results | Revenue $216.2 million up 79% year over year (consensus $209.67 million), gross margin 65%, EPS $0.00 against a $0.02 consensus loss | Caris Life Sciences Q1 2026 earnings release and TheFly summary | August 3, 2026 |
| 2026 revenue guidance | $1.0 billion to $1.02 billion, consensus about $1.01 billion | Caris Life Sciences Q1 2026 earnings call | August 3, 2026 |
| Cash and investments | $823.46 million at March 31, 2026 | StockAnalysis.com balance sheet | August 3, 2026 |
| Total debt | $381.58 million at March 31, 2026 | StockAnalysis.com balance sheet | August 3, 2026 |
| Valuation ratios | P/S (TTM) 4.88x, P/B 7.46x, P/FCF about 35.9x, forward P/E 84.79x, EV about $4.04 billion, EV/Sales 4.45x | StockAnalysis.com statistics page | August 3, 2026 |
| Analyst consensus | Buy, 13 to 14 analysts, average price target $27.00 (about 72% above the close) | StockAnalysis.com ratings and Barchart analyst ratings | August 3, 2026 |
| 52-week range | $14.19 to $42.50, stock down 46.88% over 52 weeks | Barchart and StockAnalysis.com price performance | August 3, 2026 |
| Moving averages and RSI | 50-day MA near $16.88, 200-day MA near $21.65, 14-day RSI near 41.43 | StockAnalysis.com statistics page | August 3, 2026 |
This CAI AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong. Past financial performance and revenue growth do not guarantee future results. Caris Life Sciences IPO'd on June 18, 2025 and has a limited public trading history, implied volatility near 92%, and a scheduled Q2 2026 earnings report on August 5, 2026. The stock may move sharply and can lose value significantly.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
